Articles
DGCI Starts Monitoring Remedesivir To Curb Black Marketing
by Dolly K. Digital Marketing ExecutiveDCGI or Drugs
Controller General of India recently directed State Licensing
Authorities or SLAs to keep an eye on the availability of Remdesivir injections
and prohibit its advertisement. It has been done to make sure they are
available for supply. Moreover, taking timely action helps in preventing
hoarding as well as black marketing.
It has been noticed by the union health ministry that places
like Thane and Mumbai in Maharashtra; Bhopal, Indore and Gwalior in the State
of Madhya Pradesh and Ahmedabad, along with Surat and Rajkot in Gujarat are suffering
from a shortage of Remdesivir injections. Seeing this, State licensing
authorities were directed by DCGI that they must start proper action to make
sure Remdesivir injections are available for public and private hospitals.
All SLA were also instructed to direct the enforcement staff
to keep consistent monitoring of the whole situation and keep very strict
vigilance to ensure the required availability of Remdesivir injections and
prohibit its advertisement and black marketing.
All the actions taken in this matter
should be informed to the DCGI office as early as possible. To stop hoarding
and black marketing the Remdesivir injections, the Maharashtra Food and Drug
Administration (FDA) has recently notified all the manufacturers of
Remdesivir injections to decrease the wholesale price of the drug and at the
same time has proposed to the National Pharmaceutical Pricing Authority to
monitor the price movement.
Recently, the Maharashtra FDA commissioner conducted a
meeting with all the senior officials of the Mumbai headquarters to discuss
ways for decreasing the big gap between the wholesale selling price and the
maximum retail price of Remdesivir injection. They also discussed different
ways of making this drug available to all patients at affordable rates.
The Maharashtra FDA is doing a regular review of the
Remdesivir injection availability along with other kinds of drugs in the State.
Sh. Rajendra Shingane, Maharashtra FDA Minister and Sh. Saurabh Vijay,
secretary of Department of Medical Education and Drugs Maharashtra, has given
notification to take action against the price rise of Remdesivir injection.
At present, there are six big manufacturers of Remdesivir
injection 100 mg in the whole market. To give you an idea, Dr Reddy’s Labs
REDYX costs INR 2,700, Cipla’s CIPREMI costs INR 3,000 and Cadila Healthcare’s
REMDAC costs INR 899. These rates have been recently revised by manufacturers
and have been reduced significantly to benefit the common people.
The price of Remedesivir injections was exorbitant just a few
weeks ago. It was being supplied to wholesalers and hospitals at a rate between
Rs.8000 to Rs.12000. In such a scenario, there was an uproar from several
quarters about the financial stress imposed on patients by increasing the
maximum retail price of the injection.
Thus, to curb this, DCGI has taken action by reviewing the
actual scenario and imposing monitoring programmes.
Sponsor Ads
About Dolly K. 
Digital Marketing Executive
33 connections, 4 recommendations, 183 honor points.Joined APSense since, March 24th, 2020, From New Delhi, India.
Created on May 14th 2021 06:17. Viewed 189 times.
